Press release
Hereditary Transthyretin Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis
Hereditary Transthyretin Amyloidosis
What Is the Current Hereditary Transthyretin Amyloidosis Market Size and Its Estimated Growth Rate?
In recent times, there has been a significant expansion in the market size of hereditary transthyretin amyloidosis. The market which stood at $1.36 billion in 2024 is projected to rise to $1.50 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%. The reasons behind this growth during the historic period include an escalating number of this disorder's incidences, an upsurge in research and development initiatives, a rising count of cardiac amyloidosis incidents, expanded disease awareness and advancements in healthcare infrastructure.
The market size for hereditary transthyretin amyloidosis is predicted to experience substantial expansion in the coming years, soaring to $2.14 billion in 2029 with a compound annual growth rate (CAGR) of 9.4%. Several factors contribute to this anticipated growth during the forecast period, including an increase in the aging population, higher disposable incomes, rising incidences of hereditary transthyretin amyloidosis, expansion in the production of new medicines, and growth in genetic testing. Key trends for the forecast period encompass innovative treatment offerings, improvements in diagnostic methods, strides in drug creation, the need for effective treatments, and evolutionary changes in medical technology.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003
How Are Emerging Segments Shaping the Hereditary Transthyretin Amyloidosis Market Landscape?
The hereditary transthyretin amyloidosis market covered in this report is segmented -
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
Which Growth Factors Are Influencing Hereditary Transthyretin Amyloidosis Market Expansion?
The anticipated growth of the hereditary transthyretin amyloidosis market is strongly linked to the increasing number of elderly people. This bracket consists of individuals who are 65 years of age and above, who typically require specialized medical care and assistance due to the natural process of aging. Various factors such as enhanced healthcare services and improved living conditions have led to a rise in life expectancy, thereby expanding the geriatric demographic. Hereditary transthyretin amyloidosis (hATTR), adversely affecting this demographic, leads to progressive neuropathy and cardiomyopathy, boosting the morbidity rates among the elderly. It was estimated by the Population Reference Bureau, a non-profit organization based in the US, that the resident population of those 65 and older would increase from 58 million in 2022 to 82 million by 2050, which is a surge of 47 percent. Consequently, this rise in the elderly population is acting as a significant growth driver for the hereditary transthyretin amyloidosis market.
Who Are the Dominant Players Across Different Hereditary Transthyretin Amyloidosis Market Segments?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
What Are the Latest Developing Trends in the Hereditary Transthyretin Amyloidosis Market?
Leading businesses in the hereditary transthyretin amyloidosis market are focusing on the creation of innovative treatment methods such as RNAi therapeutics which aim to limit the production of transthyretin (TTR) protein. RNAi therapeutics belong to a category of drugs that leverage RNA interference technology to suppress specific genes, thus minimizing the production of proteins that can cause disease. An illustrative example of this occurred in October 2024 when Alnylam Pharmaceuticals, Inc., a biopharmaceutical company based in the US, filed a supplementary new drug application (sNDA) to the US FDA for their drug Vutrisiran (AMVUTTRA) intended for treating transthyretin amyloidosis associated cardiomyopathy. This move highlights their original RNAi therapeutic strategy, formulated to target and decrease transthyretin (TTR) protein production, which is a principal component in disease advancement. Administering Vutrisiran subcutaneously provides a more patient-friendly and simpler dosing scheme in contrast to conventional intravenous treatments, positioning it as a potentially game-changing alternative for those suffering from this severe disorder.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/hereditary-transthyretin-amyloidosis-global-market-report
Which Geographic Regions Are Expected to Dominate the Hereditary Transthyretin Amyloidosis Market in the Coming Years?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Hereditary Transthyretin Amyloidosis Market?
2. What is the CAGR expected in the Hereditary Transthyretin Amyloidosis Market?
3. What Are the Key Innovations Transforming the Hereditary Transthyretin Amyloidosis Industry?
4. Which Region Is Leading the Hereditary Transthyretin Amyloidosis Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Transthyretin Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis here
News-ID: 4073413 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
